Related Experiment Video
Updated: Jul 18, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
Multisystem Inflammatory Syndrome in Children Associated with COVID-19 in a Tertiary Level Hospital in Portugal
Joana Vieira de Melo1, Rita Valsassina1, Ana Margarida Garcia1
1Unidade de Infecciologia Pediátrica. Hospital Dona Estefânia. Centro Hospitalar Universitário Lisboa Central. Lisboa. Portugal.
Insights
Multisystem inflammatory syndrome in children (MIS-C) is a severe COVID-19 complication. Most affected children were previously healthy, presenting with multi-organ involvement, but a small percentage experienced severe illness, highlighting the need for prompt diagnosis and treatment.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe manifestation of COVID-19.
- Understanding MIS-C characteristics is crucial for timely diagnosis and management.
Purpose of the Study:
- To describe the clinical and demographic characteristics of children diagnosed with MIS-C.
- To analyze organ system involvement and identify factors associated with severe disease presentation.
Main Methods:
- An observational descriptive study was conducted on 45 MIS-C patients admitted between April 2020 and April 2021.
- Data collected included demographics, clinical features, diagnostic tests, and treatment protocols, adhering to WHO and CDC criteria.
Main Results:
- The median age of MIS-C patients was seven years, with 60% being previously healthy. Common organ involvement included hematologic (100%), cardiovascular (97.8%), and gastrointestinal (97.8%) systems.
- Neurological and respiratory involvement correlated with more severe presentations. Laboratory markers like D-dimer, CRP, and IL-6 differed significantly between severity groups.
- While most patients received intravenous immunoglobulin and methylprednisolone, 28.8% required intensive care. Notably, 53.3% of those with cardiac MRI showed sequelae, and 90.4% had reduced exercise capacity.
Conclusions:
- MIS-C presents a wide spectrum of illness, often in previously healthy children.
- A significant minority (28.9%) experienced severe disease, emphasizing the need for high clinical suspicion for early diagnosis.
- The lack of consensus on treatment and follow-up poses challenges, underscoring the importance of timely therapeutic initiation to prevent complications.
Introduction:
Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe manifestation of coronavirus disease 2019 (COVID-19). The aim of this study was to describe the characteristics of children with MIS-C admitted to a pediatric tertiary hospital in Portugal.
Material And Methods:
Observational descriptive study of MIS-C patients admitted between April 2020 and April 2021. Demographic and clinical characteristics, diagnostic tests, and treatment data were collected. The diagnosis of MIS-C was based on the World Health Organization and Centers for Disease Control and Prevention criteria.
Results:
We reported 45 children with MIS-C. The median age was seven years (IQR 4 - 10 years) and 60.0% were previously healthy. SARS-CoV-2 infection was confirmed in 77.8% by RT-PCR or antibody testing for SARS-CoV-2, and in 73.3%, an epidemiological link was confirmed. All the patients had a fever and organ system involvement: hematologic (100%), cardiovascular (97.8%), gastrointestinal (97.8%), mucocutaneous (86.7%), respiratory (26.7%), neurologic (15.6%), and renal (13.3%) system. Neurological (p = 0.035) and respiratory (p = 0.035) involvement were observed in patients with a more severe presentation. There was a significant difference of medians when comparing disease severity groups, namely in the values of hemoglobin (p = 0.015), lymphocytes (p = 0.030), D-dimer (p = 0.019), albumin (p < 0.001), NT-proBNP (p = 0.005), ferritin (p = 0.048), CRP (p = 0.006), procalcitonin (p = 0.005) and IL-6 (p = 0.002). From the total number of children, 93.3% received intravenous immunoglobulin, 91.1% methylprednisolone, and one patient (2.2%) received anakinra. Thirteen patients (28.8%) required intensive care and there were no deaths. Of the 21 patients evaluated, 90.4% had reduction of exercise capacity and of the 15 patients who underwent cardiac magnetic resonance, 53.3% had sequelae of cardiac injury.
Conclusion:
We observed a large spectrum of disease presentation in a group of patients where most were previously healthy. A small percentage of patients (28.9%) had a severe presentation of the disease. MIS-C is a challenge in current clinical practice and its diagnosis requires a high level of clinical suspicion as the timely initiation of therapy is essential to prevent complications. However, there is no scientific consensus on the treatment and follow-up of these patients.
Related Concept Videos
Pneumonia III: Complications and Assessment
Bacterial Meningitis
Viral Meningitis
Cytomegalovirus Disease
Coronavirus
Respiratory Syncytial Virus Disease
